Related Experiment Video
Updated: May 6, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Increased tissue levels of omega-3 polyunsaturated fatty acids prevents pathological preterm birth
Aki Yamashita1, Kei Kawana, Kensuke Tomio
1Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Insights
Omega-3 fatty acids, like eicosapentaenoic acid (EPA), reduce preterm birth by decreasing inflammation. Resolvin E3 (RvE3), derived from EPA, shows potential as a new therapeutic to prevent preterm birth.
Area of Science:
- Reproductive biology
- Inflammation research
- Nutritional science
Background:
- Preterm birth is a significant obstetric complication often linked to inflammation.
- Omega-3 polyunsaturated fatty acids (PUFAs) possess known anti-inflammatory properties.
Purpose of the Study:
- To investigate the role of omega-3 fatty acids in preventing lipopolysaccharide (LPS)-induced preterm birth.
- To explore the potential of resolvin E3 (RvE3) as a therapeutic agent for preterm birth prevention.
Main Methods:
- Utilized fat-1 transgenic mice, which convert omega-6 to omega-3 fatty acids, to study preterm birth incidence.
- Analyzed uterine gene expression (IL-6, IL-1β) and cervical macrophage infiltration.
- Performed lipid metabolomics to identify key metabolites, including 18-hydroxyeicosapentaenoate and RvE3.
- Administered RvE3 to LPS-exposed pregnant wild-type mice to assess its efficacy.
Main Results:
- Abundance of omega-3 fatty acids in fat-1 mice reduced LPS-induced preterm birth.
- Fat-1 mice exhibited decreased uterine IL-6 and IL-1β gene expression and fewer cervical macrophages.
- Elevated levels of 18-hydroxyeicosapentaenoate, metabolized to RvE3, were observed in fat-1 mice.
- RvE3 administration significantly lowered preterm birth incidence in LPS-exposed wild-type mice.
Conclusions:
- Increased omega-3 fatty acid levels can mitigate inflammation-driven preterm birth.
- Resolvin E3 (RvE3) is identified as a key anti-inflammatory metabolite derived from eicosapentaenoic acid (EPA).
- RvE3 demonstrates therapeutic potential for preventing preterm birth.
Abstract:
Omega-3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA) have anti-inflammatory effects. Preterm birth is an important problem in modern obstetrics and one of the main causes is an inflammation. We here showed that abundance of omega-3 fatty acids reduced the incidence of preterm birth induced by LPS with fat-1 mice, capable of converting omega-6 to omega-3 fatty acids. We also indicated that the gene expression of IL-6 and IL-1β in uteruses and the number of cervical infiltrating macrophages were reduced in fat-1 mice. The analyses of lipid metabolomics showed the high level of 18-hydroxyeicosapentaenoate in fat-1 mice, which was derived from EPA and was metabolized to anti-inflammatory product named resolvin E3 (RvE3). We finally showed that the administration of RvE3 to LPS-exposed pregnant wild type mice lowered the incidence of preterm birth. Our data suggest that RvE3 could be a potential new therapeutic for the prevention of preterm birth.
More Related Videos
Related Concept Videos
Development of the Oral Microbiota
Environmental Influences on Intelligence
Teratogenicity
Atherosclerosis III: Management

